News - Astellas Pharma, Immunologicals


Popular Filters

FDA backs Astellas' Astragraf XL for kidney transplant rejection prophylaxis


The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Astragraf…

Astellas PharmaAstragraf XLImmunologicalsNorth AmericaPharmaceuticalRegulationtacrolimus

Additional indications in Japan for Roche's Avastin and Astellas' Prograf


Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Novartis expands transplant portfolio with first branded generic tacrolimus


Swiss drug major Novartis has announced the US introduction and availability of Hecoria (tacrolimus)…

Astellas PharmaGenericsHecoriaImmunologicalsMarkets & MarketingNorth AmericaNovartisPrografSandoztacrolimus

EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor


In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal…

AdvagrafAnti-Arthritics/RheumaticsAstellas PharmaCardio-vascularEuropeImmunologicalsPharmaceuticalProtelosRegulationServier

Substitution of brand name tacrolimus with generic proves safe for transplant recipients


The substitution of a brand name immunosuppressive drug with a generic (manufactured by Novartis generics…

Astellas PharmaBiotechnologyGenericsImmunologicalsPrografResearchtacrolimus

Astellas in-licenses antibody from Evec; Mitsubishi Tanabe deal with Synageva


Japanese biotech firm Evec has entered a license agreement for one of its fully-human antibodies against…

Asia-PacificAstellas PharmaBiotechnologyEvecImmunologicalsLicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Combination of Advagraf and CellCept led to less organ rejection; study


For the thousands of patients who receive kidney transplants in the USA each year, preventing organ rejection…

AdvagrafAstellas PharmaCellCeptImmunologicalsPharmaceuticalResearchRoche

Back to top